Hemoporfin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Hemoporfin is a porphyrin derivative combined with vitamin B12 for the treatment of asthenia.

Generic Name
Hemoporfin
DrugBank Accession Number
DB16183
Background

Hemoporfin is under investigation in clinical trial NCT03125057 (A Pilot Study of Hemoporfin PDT in Children With Port-wine Stain).

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 598.7
Monoisotopic: 598.27913496
Chemical Formula
C34H38N4O6
Synonyms
  • Haematoporphyrin
  • Hematoporphyrin
  • Hematoporphyrin ix
  • Hemoporfin
  • Photodyn
External IDs
  • NSC-267084
  • NSC-59265

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Used in combination to treatAstheniaCombination Product in combination with: Cyanocobalamin (DB00115)••• •••••••••• ••• ••••••••
Associated Therapies
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
PadeliporfinHemoporfin may increase the photosensitizing activities of Padeliporfin.
Porfimer sodiumHemoporfin may increase the photosensitizing activities of Porfimer sodium.
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Hemoporfin.
VerteporfinHemoporfin may increase the photosensitizing activities of Verteporfin.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Hematoporphyrin dihydrochlorideO535A6S0T217696-69-4QCLJGYHFHNRFIL-UDHHKLSBSA-N

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
HBT6M5H379
CAS number
14459-29-1
InChI Key
UJKPHYRXOLRVJJ-AMPAVEGJSA-N
InChI
InChI=1S/C34H38N4O6/c1-15-21(7-9-31(41)42)27-14-28-22(8-10-32(43)44)16(2)24(36-28)12-29-34(20(6)40)18(4)26(38-29)13-30-33(19(5)39)17(3)25(37-30)11-23(15)35-27/h11-14,19-20,36-37,39-40H,7-10H2,1-6H3,(H,41,42)(H,43,44)/b23-11-,24-12-,25-11-,26-13-,27-14-,28-14-,29-12-,30-13-
IUPAC Name
3-[20-(2-carboxyethyl)-10,15-bis(1-hydroxyethyl)-5,9,14,19-tetramethyl-21,22,23,24-tetraazapentacyclo[16.2.1.1^{3,6}.1^{8,11}.1^{13,16}]tetracosa-1,3(24),4,6,8,10,12,14,16(22),17,19-undecaen-4-yl]propanoic acid
SMILES
CC(O)C1=C2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C)=C5C(C)O)C(C)=C4CCC(O)=O)C(CCC(O)=O)=C3C)=C1C

References

General References
  1. AIFA: Tonogen (Cyanocobalamin, Hematoporphyrin Dihydrochloride) Oral Powder for Solution [Link]
ChemSpider
16739170
RxNav
5164
ChEBI
36162
ChEMBL
CHEMBL403729

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentPort-wine Stains (PWS)3
1CompletedTreatmentLung Cancer1
Not AvailableNot Yet RecruitingTreatmentCholangiocarcinoma1
Not AvailableRecruitingTreatmentNon-Resectable Cholangiocarcinoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Powder, for solutionOral
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0372 mg/mLALOGPS
logP2.74ALOGPS
logP4.45Chemaxon
logS-4.2ALOGPS
pKa (Strongest Acidic)3.75Chemaxon
pKa (Strongest Basic)5.06Chemaxon
Physiological Charge-2Chemaxon
Hydrogen Acceptor Count8Chemaxon
Hydrogen Donor Count6Chemaxon
Polar Surface Area172.42 Å2Chemaxon
Rotatable Bond Count8Chemaxon
Refractivity166.91 m3·mol-1Chemaxon
Polarizability69.15 Å3Chemaxon
Number of Rings5Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-01qa-0000090000-ddb64d2f61ce64d116fd
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-01rj-0000090000-21193b74e23e45e23736
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-03di-0000090000-67c1900e710daa9e9124
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-052r-1000090000-02d152ef49a64c2e3c1c
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-000i-0000090000-34099e0f169714a76bf6
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-052r-0000090000-148731f53426d2855bde
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-247.62666
predicted
DeepCCS 1.0 (2019)
[M+H]+249.49495
predicted
DeepCCS 1.0 (2019)
[M+Na]+255.23535
predicted
DeepCCS 1.0 (2019)

Drug created at December 15, 2020 18:14 / Updated at May 05, 2021 20:32